Melanoma News & Features
Investigators have discovered one way in which melanoma becomes resistant to a particular form of targeted therapy, a discovery that may lead to a new melanoma target or prompt new designs for treatment.
A new triple combination therapy has shown signs that it can more effectively control advanced melanoma that previous, dual-therapy combinations.
No statistical difference was seen in 5-year survival for melanoma patients with NRAS or BRAF mutations.
Surgery is delayed in 1 in 5 Medicare patients with melanoma.
Incidence of pediatric melanoma in the United States has declined from 2004-2010.
- Vitamin D and prostate cancer: Higher intake improves active surveillance outcomes
- Triple combination of two targeted therapies + immunotherapy is more effective in advanced melanoma
- Muscle-building supplements may be associated with testicular cancer
- Promising drug target identified in medulloblastoma
- Physical activity associated with less chemo-induced peripheral neuropathy
- mHealth app assesses breast cancer risk and aids prevention
- Socioeconomic factors increase mortality after lung cancer surgery
- Half of older U.S. adults take aspirin as preventive medicine
- Cardiorespiratory fitness linked with decreased metabolic syndrome risk among smokers
- Adjuvant chemotherapy in non-small cell lung cancer: State-of-the-art
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|